Amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of actinomycotic mycetoma

J Am Acad Dermatol. 1987 Sep;17(3):443-8. doi: 10.1016/s0190-9622(87)70227-8.

Abstract

We report the excellent therapeutic response obtained with amikacin alone and in combination with trimethoprim-sulfamethoxazole in the treatment of 15 patients with actinomycotic mycetoma who had a poor response to the traditional pharmacologic agents and/or in whom important organs such as lungs, spinal cord, and bone were involved. We evaluated the results by clinical, radiologic, and laboratory tests. No important side effects were detected during or after the therapy.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Adult
  • Amikacin / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use*
  • Clinical Trials as Topic
  • Drug Combinations / therapeutic use
  • Drug Therapy, Combination
  • Female
  • Humans
  • Male
  • Mycetoma / drug therapy*
  • Mycetoma / microbiology
  • Nocardia / isolation & purification
  • Prospective Studies
  • Remission Induction
  • Sulfamethoxazole / therapeutic use*
  • Trimethoprim / therapeutic use*
  • Trimethoprim, Sulfamethoxazole Drug Combination

Substances

  • Anti-Bacterial Agents
  • Drug Combinations
  • Trimethoprim, Sulfamethoxazole Drug Combination
  • Amikacin
  • Trimethoprim
  • Sulfamethoxazole